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Venoms consist of toxic components that are deliv-
ered to their victims via bites or stings. Venoms
also represent a major class of allergens in humans.
Phospholipase A2 (PLA2) is a conserved component
of venoms from multiple species and is the major
allergen in bee venom. Here we examined how bee
venom PLA2 is sensed by the innate immune system
and induces a type 2 immune response in mice. We
found that bee venom PLA2 induced a T helper
type 2 (Th2) cell-type response and group 2 innate
lymphoid cell activation via the enzymatic cleavage
of membrane phospholipids and release of inter-
leukin-33. Furthermore, we showed that the IgE
response to PLA2 could protect mice from future
challenge with a near-lethal dose of PLA2. These
data suggest that the innate immune system can
detect the activity of a conserved component of
venoms and induce a protective immune response
against a venom toxin.INTRODUCTION
Viral, bacterial, and fungal infections are detected by the innate
immune system through the recognition of pathogen-associated
molecular patterns (PAMPs) by pattern-recognition receptors
(PRRs), such as the Toll-like receptors. PAMPs consist of micro-
bial molecules that are unique to microbial nonself, essential for
microbial fitness, and conserved within a class of microbes.
These features of PAMPs allow PRRs to distinguish self from
infectious nonself and to target appropriate immune responses
toward foreign antigens. Recognition of PAMPs by PRRs leads
to the induction of antimicrobial T helper type 1 (Th1), Th17,
and associated immunoglobulin G2 (IgG2) responses (Palm
and Medzhitov, 2009).
In contrast to infections with bacteria, viruses, and fungi, para-
sitic worms (helminths) and allergens induce Th2 and IgE re-
sponses. The mechanisms by which the innate immune system
recognizes helminths and allergens and instructs Th2 and IgE
responses remain largely unknown, but appear to be indepen-976 Immunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc.dent of PRRs (Palm et al., 2012). Instead, it has been proposed
that allergens and helminths are detected through sensing of
the outcomes of their unique activities (Donnelly et al., 2006;
Palm et al., 2012; Pulendran and Artis, 2012). For example, pro-
teases excreted by helminths and protease allergens induce
type 2 immune responses in a manner that is dependent on their
enzymatic activities (Donnelly et al., 2006). It has also been sug-
gested that the type 2 immune response might be connected to
sensing of tissue damage or tissue disruption and that one
purpose of the allergic response is to protect against or repair
allergen- or helminth-mediated tissue damage (Palm et al.,
2012; Profet, 1991; Allen and Wynn, 2011). Indeed, although
allergens are often thought of as innocuous environmental sub-
stances, many allergens clearly have noxious activities that
can induce tissue damage (Palm et al., 2012; Profet, 1991).
Recent studies have revealed an important role for the epithe-
lial cell-derived cytokines IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP) in the induction of type 2 responses to
helminths and allergens (Pulendran and Artis, 2012). While
IL-25 and TSLP act as traditional cytokines and are transcription-
ally regulated, IL-33 is constitutively expressed in barrier epi-
thelial cells and lacks a signal sequence. The physiological
mechanisms of IL-33 release remain unclear; however, it is
thought that IL-33 release is triggered by necrotic cell death or
cell lysis (Liew, 2012). IL-33 has long been known as a potent
stimulator of type 2 cytokine production by Th2 cells; more
recently, IL-33 has been shown to activate group 2 innate
lymphoid cells (ILC2s), which are innate producers of type 2 cy-
tokines such as IL-5 and IL-13 (Walker and McKenzie, 2013).
Venoms consist of a complex mixture of toxic components
that are delivered to their victims via bites or stings, and are
used by various animal species, including insects, arachnids,
cnidaria, and reptiles, for defense and predation (Fry et al.,
2009). Venoms from various species can induce Th2 and IgE
responses and therefore represent a major class of allergens
(Bircher, 2005; Habermann, 1972; Madero et al., 2009). Type 2
responses to western honey bee (Apis mellifera) venom are
well documented in both mice and humans (Bircher, 2005; Hab-
ermann, 1972; Mu¨ller, 2010). Bee venom contains a mixture of
enzymes, cell-lytic peptides, proteases, and bioactive amines.
The two major proteinaceous components of bee venom are
melittin, a 23-amino-acid cationic cell-lytic peptide, and Phos-
pholipase A2 (PLA2), an enzyme that hydrolyzes membrane
phospholipids to produce lysophospholipids and arachidonic
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Figure 1. Bee Venom and bvPLA2 Induce
Th2 Differentiation and Antigen-Specific
IgE and IgG1 Production
(A) Percent IL-4eGFP+ T cells from popliteal LNs of
4get mice 5 days after subcutaneous immuniza-
tion with PBS, bee venom, bvPLA2, or melittin.
(B) Cytokine production after in vitro restimulation
of LN CD4+ T cells from BALB/c mice 5 days after
subcutaneous immunization with OVA in the
absence or presence of bvPLA2.
(C) Serum OVA-specific IgE and IgG1 in BALB/c
mice after subcutaneous immunization with OVA
alone or in the presence of bee venom, bvPLA2, or
melittin on days 0 and 21. All error bars show SEM.
*p < 0.05; **p < 0.005; ***p < 0.001. Data are
representative of at least three experiments. See
also Figure S1.
Immunity
Venom Phospholipase A2-Induced Type 2 Responsesacid (Habermann, 1972). PLA2 is the major allergen in bee
venom (Sobotka et al., 1976), and bvPLA2 enzymatic activity is
necessary for its ability to induce an IgE response in mice (Dudler
et al., 1995). Furthermore, PLA2s are integral and conserved
components of venoms from divergent species, including
venomous spiders, scorpions, bees, and snakes; in addition,
PLA2 is also a common component of hematophageous fluids
from some blood-feeding animals, such asmosquitoes and ticks
(Fry et al., 2009; Habermann, 1972). Notably, exposure to
bvPLA2 leads to damage of cellular membranes and, at high
concentrations, necrotic cell death (Ownby et al., 1997).
Because venoms represent amajor class of noxious allergens,
we wished to examine the mechanism by which venoms are
sensed by the innate immune system and induce a type 2
immune response. We found that bvPLA2 induced type 2
immune responses in vivo in a manner that was dependent on
its enzymatic activity and on the interleukin-33 (IL-33) receptor
component ST2. PLA2 from snake venom also induced a Th2
response, which suggests that PLA2s may represent a type 2-
inducing enzymatic activity that is a common component of
this class of allergens. Finally, we implicated the IgE response
to bvPLA2 in protection against future exposure to this noxious
venom component.
RESULTS
Bee Venom PLA2 Induces a Type 2 Immune Response
To examine the allergenicity of bee venom and its components,
we first tested the ability of bee venom to induce a Th2 response
by measuring IL-4 transcription in CD4+ T cells by using IL-4-
IRES-eGFP (4get) reporter mice (Mohrs et al., 2001). Immuniza-
tions with 100 mg bee venom (equivalent to approximately 1 bee
sting) induced the accumulation of IL-4eGFP expressing CD4+
T cells in the draining lymph node 5 days after subcutaneous
immunization (Figure 1A). Immunization with an equivalentImmunity 39, 976–985, Ndose of purified bvPLA2 induced even
greater Th2 differentiation than whole
bee venom, whereas melittin was less
efficient at inducing a Th2 response.
Immunization with bvPLA2 admixed with
endotoxin-free ovalbumin (OVA) alsoinduced an OVA-specific Th2 response that was characterized
by secretion of IL-4, IL-5, and IL-13 after restimulation of isolated
CD4+ T cells with OVA in vitro (Figure 1B). In contrast, production
of interferon-g (IFN-g) and IL-17 after restimulation was negli-
gible (data not shown). These results demonstrate that bvPLA2
is a potent inducer of the Th2 response.
We next examined venom-induced IgG1 and IgE production,
which requires cognate help from IL-4-producing T cells. Bee
venom, melittin, and bvPLA2 induced antigen-specific IgG1
and IgE responses to admixed endotoxin-free OVA, whereas
OVAalonedid not induce a robust antibody response (Figure 1C).
As compared to total bee venom and melittin, bvPLA2 induced
the strongest anti-OVA IgG1 and IgE responses. OVA-specific
IgG2c production after immunization was undetectable under
all immunization conditions (data not shown). Bee venom and
bvPLA2, but not melittin, also induced an increase in total serum
IgE. The IgE response to bee venomand bvPLA2 remained intact
in Toll-like receptor 2 (TLR2) and TLR4-deficient mice, suggest-
ing that the ability of bee venom and bvPLA2 to induce IgE
production is not due to contamination with bacterial PAMPs,
such as lipopolysaccharide (see Figure S1A available online).
The total IgE response induced by bee venom and bvPLA2
was similar in kinetics and magnitude to the IgE response that
is induced by themodel cysteine protease allergen from papaya,
papain (Figure S1A; Sokol et al., 2008). Papain has been shown
to induce recruitment of dendritic cells and basophils to the
draining lymph node after subcutaneous immunization. Similarly,
bvPLA2 immunization induced the recruitment of dendritic cells
and basophils to the draining lymph node 18 hr or 3 days after
immunization, respectively (Figures S1B and S1C).
Many allergens can directly activate innate type 2 cells, such
as basophils and mast cells, in an IgE-independent manner.
For example, human basophils respond to the proteolytic activity
of Der p 1 (Phillips et al., 2003), and papain directly stimulates
murine basophils to produce IL-4 in a protease-dependentovember 14, 2013 ª2013 Elsevier Inc. 977
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Figure 2. PLA2 Induces a Th2 Response
through Cleavage of Membrane Phospho-
lipids to Produce Lysophospholipids
(A–E) CD4+ GFP+ T cells from popliteal LNs of 4get
mice 5 days after subcutaneous immunization with
(A) active bvPLA2 or heat-inactivated bvPLA2 (C)
OVA in the presence of LPC or AA (D) OVA,
Crotalus atrox venom or Agkistrodon contortrix
venom (E) OVA, Crotalus adamanteus venom, or
Crotalus adamanteus PLA2. (B) PLA2 hydrolyzes
phospholipids into arachidonic acid (AA) and
lysophospholipids (e.g., LPC). All error bars show
SEM. *p < 0.05; **p < 0.005. Data are representa-
tive of at least three experiments. See also Fig-
ure S2.
Immunity
Venom Phospholipase A2-Induced Type 2 Responsesmanner (Sokol et al., 2008). Similar to papain, PLA2 was a potent
inducer of IL-4 transcription and secretion by in vitro-derived
basophils (Figures S1D and S1E). The ability of bvPLA2 to induce
IL-4 secretion by basophils also did not require TLR2 or TLR4,
again suggesting that bvPLA2 allergenicity is not due to contam-
ination with bacterial products (data not shown).
The T Cell Response to bvPLA2 Is Dependent on PLA2
Activity
Many known allergens are enzymes, and the enzymatic activities
of many of these allergens are required to induce Th2 and IgE
responses (Palm et al., 2012; Pulendran and Artis, 2012). A
previous study that used enzymatically inactive mutants of
bvPLA2 found that the enzymatic activity of bvPLA2 is necessary
for its ability to induce anti-PLA2 IgE production in mice (Dudler978 Immunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc.et al., 1995). We therefore tested whether
PLA2 activity is also critical for its ability to
induce Th2 responses. We found that
heat inactivation of bvPLA2 eliminates
its ability to induce a Th2 response in
4get mice (Figure 2A), which suggests
that the enzymatic activity of bvPLA2 is
necessary to induce the Th2 response.
PLA2s hydrolyze membrane phos-
pholipids to produce lysophospholipids,
such as lysophosphatidylcholine (LPC),
and arachidonic acid (AA), which is the
precursor of eicosanoids (Figure 2B)
(Burke and Dennis, 2009). Because the
allergenicity of bvPLA2 is dependent on
its enzymatic activity, we sought to test
which product of bvPLA2 activity is res-
ponsible for its ability to induce a Th2
response. We found that LPC, but not
AA, induced a Th2 response in 4get mice
when admixed with OVA (Figure 2C).
LPC, but not AA, also induced IL-4 pro-
duction by in vitro-derived basophils (Fig-
ure S2A). LPC has been shown to activate
the G protein-coupled receptor 132
(Gpr132, also referred to as G2A), which
led us to test the role of G2A in the Th2
response to PLA2 (Kabarowski et al.,2001). Surprisingly,Gpr132/mice showed intact Th2cell differ-
entiation in response to bvPLA2 immunization (Figure S2B). Thus
the Th2-inducing activity of LPCmight bemediated by a different
receptor or its effectmaybe receptor independent—for example,
LPC also acts as a detergent and can induce cell lysis. In this
regard, it is notable that Phospholipase D, which cleaves mem-
brane phospholipids at a different site from PLA2, also induced
a Th2 response (data not shown). These data suggest that
PLA2 induces the Th2 response by hydrolyzingmembrane phos-
pholipids to produce lysophospholipids, such as LPC.
The Immune System Senses PLA2s from Multiple
Venomous Species
Because PLA2s are a conserved component of venoms from
divergent animal species, we hypothesized that detection of
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Figure 3. bvPLA2-Induced Th2 Responses Are Dependent upon
MyD88 and the IL-33-Receptor ST2
(A–C) Cytokine production after in vitro restimulation of LN CD4+ T cells from
(A) BALB/c and Myd88/ BALB/c (B) C57Bl/6, Myd88/ C57Bl/6,
Tlr2/;Tlr4/, Tlr9/, Myd88/;Trif/, Il1r1/, and Il18r1/, and (C)
C57Bl/6 and Il1rl1/ (ST2-deficient) mice 5 days after immunization with OVA
and bvPLA2.
(D) Cytokine production after in vitro restimulation of LN CD4+ T cells
from C57Bl/6 and Il1rl1/ mice 5 days after immunization with OVA with
or without LPC. (E) Cytokine production after in vitro restimulation of LN
CD4+ T cells from MyD88fl/fl (WT) and MyD88fl/fl;Cd4-Cre mice 5 days after
Immunity
Venom Phospholipase A2-Induced Type 2 Responses
IPLA2 activity might be used by the innate immune system as a
way to detect multiple venoms. Consistent with this possibility,
venoms from the Western Diamondback rattlesnake (Crotalus
atrox) and Northern Copperhead (Agkistrodon contortrix moka-
sen) efficiently induced Th2 responses (Figure 2D) and induced
IL-4 production by in vitro-derived basophils (Figure S2C).
Furthermore, similar to bvPLA2, purified PLA2 from the Eastern
Diamondback rattlesnake (Crotalus adamanteus) was sufficient
to induce a Th2 response that was comparable in magnitude
to the response induced by total C. adamanteus venom (Fig-
ure 2E). These data suggest that PLA2, a conserved component
of multiple venoms, can be used by the immune system to detect
envenomation, which results in the induction of a Th2 response.
Th2 Responses Induced by bvPLA2 Are Dependent on
MyD88 and the IL-33 Receptor ST2
We next asked which innate immune pathways are involved in
the induction of Th2 responses to bvPLA2. MyD88 is the central
signaling adaptor for the TLRs and for receptors that recognize
the IL-1 family of cytokines, including IL-1, IL-18, and IL-33
(Dinarello, 2009). MyD88 is also critical for the initiation of T cell
responses to many bacterial and viral pathogens (Palm and
Medzhitov, 2009). We therefore tested the role of MyD88 in the
bvPLA2-induced Th2 response. We found that Th2 responses
induced by bvPLA2 were largely dependent on MyD88 (Figures
3A and 3B). In contrast, bvPLA2-induced Th2 responses were
independent of TLR2, TLR4, TLR9, IL-1R, and IL-18R (Figure 3B),
thus ruling out the contribution of TLRs, IL-1, and IL-18 in the
response to bvPLA2.
TLRs and the cytokines IL-1 and IL-18 are critical for the initi-
ation and coordination of Th1 and Th17 responses. In contrast,
IL-33 is a potent inducer of type 2 cytokine production by
T cells, basophils, and ILC2s (Schmitz et al., 2005). We tested
the role of IL-33 in the Th2 response to bvPLA2 by examining
mice lacking ST2, which is a component of the receptor for
IL-33 (Townsend et al., 2000). We found that ST2-deficient
mice showed reduced Th2 responses to bvPLA2 (Figure 3C).
Furthermore, LPC-induced Th2 responses were also dependent
on ST2 (Figure 3D). This suggests that bvPLA2 induces a Th2
response by stimulating production of LPC, which then leads
to the induction of a Th2 response through activation of ST2.
IL-33 can induce Th2 responses through its actions on
dendritic cells or through a direct effect on T cells themselves
(Besnard et al., 2011; Humphreys et al., 2008; Liew, 2012). We
were interested in identifying which cell type IL-33 acted upon
to induce Th2 differentiation in response to bvPLA2. By using
conditional knockout mice that lack MyD88 specifically in
CD4+ T cells, we found that Th2 responses to bvPLA2 were
largely dependent on MyD88 expression in T cells (Figure 3E).
In contrast, mice lacking MyD88 specifically in dendritic cells
showed normal Th2 responses to bvPLA2 immunization (data
not shown). These data demonstrate that IL-33 controls the
Th2 response to bvPLA2 by acting directly on CD4+ T cells,
whereas IL-33 signaling in dendritic cells is dispensable for this
response.immunization with OVA and bvPLA2. All error bars show SEM. N.S. p >
0.05; *p < 0.05; ***p < 0.001. Data are representative of at least three
experiments.
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Figure 4. bvPLA2 and LPC Induce IL-33 Release and Activation of ILC2s
(A and C) IL-33 concentration in peritoneal fluid after (A) bvPLA2 and (C) LPC intraperitoneal immunizations.
(B and D) IL-33 concentration in supernatants of cells overexpressing IL-33 after stimulation with (B) bvPLA2 and (D) LPC.
(E) Peritoneal exudate collected from WT and Il1rl1/ (ST2-deficient) mice on day 4 after daily intraperitoneal injections with PLA2 for 3 days. FACS plots show
group 2 innate lymphoid cells, as defined by CD45+LinCD90.2+, after ex vivo stimulation with PMA and ionomycin to induce cytokine production. Eosinophils,
mast cells, and neutrophils were defined bymorphology (n = 5mice/group). All error bars showSEM. *p < 0.05; **p < 0.005; ***p < 0.001. Data are representative of
at least two experiments. See also Figure S3.
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Venom Phospholipase A2-Induced Type 2 ResponsesbvPLA2 Induces IL-33 Release and ST2-Dependent
Activation of ILC2s
Considering that ST2 expression was required for activation of
bvPLA2-induced Th2 responses, we were interested in deter-
mining whether bvPLA2 could induce the release of IL-33.
IL-33 lacks a signal sequence and its physiological mechanism
of release remains unclear. However, it has been suggested
that IL-33 release might be triggered by cell damage and/or
necrotic cell death (Liew, 2012). Because PLA2s cause mem-
brane damage and can trigger cell death at high concentrations,
we tested whether bvPLA2 could trigger IL-33 release. We found
that bvPLA2 could induce IL-33 production in vivo after intraper-
itoneal injection (Figure 4A) and in vitro by using a cell line that
overexpresses IL-33 (Figure 4B). Similarly, LPC could also
induce IL-33 release both in vivo and in vitro (Figures 4C and
4D), suggesting that bvPLA2 might act by producing LPC, which
then leads to IL-33 release. These data suggest that the ability of980 Immunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc.PLA2 to induce the type 2 immune response might be related to
its ability to induce membrane damage and, therefore, IL-33
release.
Because IL-33 is released from necrotic cells, we also exam-
ined the role of regulated necrosis, or necroptosis, in the Th2
response to PLA2 (Kaczmarek et al., 2013). However, mice defi-
cient in RIP3, which is required to induce programmed necrosis
(Vandenabeele et al., 2010), exhibited intact Th2 responses after
immunization with bvPLA2 (Figure S3).
IL-33 has recently become well known as a potent stimulator
of ILC2s, which are innate producers of type 2 cytokines such
as IL-5 and IL-13 and thereby drive eosinophilia and goblet cell
hyperplasia (Walker and McKenzie, 2013). Because we found
that bvPLA2 induces IL-33 release in vivo, we wondered whether
PLA2 might also induce the activation of ILC2s. Intraperitoneal
injection with bvPLA2 led to the appearance of IL-5 expressing
ILC2s in the peritoneal cavity and eosinophilia (Figure 4E).
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Figure 5. Immunization with bvPLA2 Protects from Subsequent
Challenge with a Near-Lethal Dose of bvPLA2 in a B Cell- and
FcεR-Dependent Manner
(A) Rectal temperature measurements of naive or immunized C57Bl/6 mice
challenged with a near-lethal dose of bvPLA2. Mice were immunized i.p. for 6
consecutive weeks with 50 mg bvPLA2 before challenge.
(B) Rectal temperatures of naive or immunized C57Bl/6 and B cell-deficient
muMT (Ighm/) mice treated as in (A).
(C) Rectal temperatures of naive or immunized C57Bl/6 and Fcer1a/ mice
treated as in (A). *p < 0.05; **p < 0.005; ***p < 0.001. All error bars show SEM.
Data are representative of at least three experiments. See also Figure S4.
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eosinophilia were reduced in ST2-deficient mice. These data
suggest that bvPLA2 induces ILC2 activation by triggering the
release of IL-33.
The bvPLA2-Induced IgE Response Is Independent of
ST2
Because we found that IL-33 is critical for inducing both Th2 and
ILC2 responses to PLA2, we next examined the requirement for
IL-33 in the induction of IgE responses. Because cognate help
from Th2 cells is required for the IgE response, we expected
that the PLA2-induced IgE response would be reduced in ST2-Ideficient mice. However, PLA2-induced IgE responses were
normal in ST2-deficient mice (Figure S4A). One possible reason
for the differential requirement for ST2 in Th2 versus IgE
responses is that we examine the Th2 response after a primary
immunization, whereas the IgE response is only detectable after
a secondary immunization. Therefore, we could not compare the
requirement for ST2 during primary Th2 and IgE responses.
However, when we examined the secondary Th2 response
induced by bvPLA2, we found that, like the IgE response, it
remained largely intact even in the absence of ST2 (Figure S4A).
It is notable that a similar discrepancy between Th2 and IgE
responses also exists in response to Schistosoma mansoni
eggs (Townsend et al., 2000) and the protease allergen papain:
Th2 responses induced by papain are MyD88 dependent (Fig-
ure S4B), whereas IgE responses areMyD88 independent (Sokol
et al., 2008).
An FcεR1a-Dependent Immune Response to bvPLA2
Helps to Protect against bvPLA2-Mediated Toxicity
We were next interested in testing the potential role of the
immune response to venoms in defense against the noxious
effects of envenomation. Because antivenoms function via
transfer of neutralizing antivenom IgGs (Chippaux and Goyffon,
1998) and neutralizing anti-PLA2 antibodies have been observed
in humans (Mohammed and El-Karemi, 1961), we examined
whether repeated immunizations with PLA2 in mice could pro-
vide protection from the noxious effects of envenomation
through induction of an antibody response. We found that
weekly intraperitoneal immunizations with low dose bvPLA2 for
6 weeks could indeed protect against challenge with a near-
lethal dose of bvPLA2 (Figure 5A) and that B cell-deficient
mice failed to acquire protection (Figure 5B). We initially
expected to find that neutralizing IgGs were responsible for
this protection; however, transfer of serum from mice that were
resistant to PLA2 challenge due to repeated PLA2 administration
failed to provide any measurable protection from high-dose
PLA2 exposure (data not shown).
Whereas the concentration of IgG in the serum is high in
immunized animals, IgE is mostly bound to the FcεR on mast
cells and basophils, and only very low amounts of free IgE
are present in the serum. We therefore next considered the pos-
sibility that IgE rather than IgG1 might provide protection from
envenomation. Notably, mast cells have been shown to directly
detoxify venom components and to protect from venom-
mediated toxicity and death (Akahoshi et al., 2011; Higginbo-
tham, 1965; Higginbotham and Karnella, 1971; Metz et al.,
2006). This raises the possibility that IgE-dependent responses
to venoms might also provide protection against venom
toxins. We sought to test this by examining whether the IgE
response to bvPLA2 was critical for protection against bvPLA2
toxicity. We found that protection from bvPLA2 challenge
was partially dependent on the FcεR, because mice deficient
for FcεR1a (Dombrowicz et al., 1993) did not acquire full pro-
tection against PLA2 toxicity as compared to immunized wild-
type (WT) mice (Figure 5C). Importantly, mast cells from
FcεR1a-deficient mice appear to develop and function normally
(Dombrowicz et al., 1993), and FcεR1a deficiency had no effect
on the sensitivity of unimmunized mice to PLA2 toxicity
(Figure 5C).mmunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc. 981
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induced by PLA2 is independent of MyD88 and ST2, we wished
to test directly whether deficiency in IL-33 signaling might still
affect development of protection against envenomation. How-
ever, as expected from our earlier finding that antibody
responses to repeated immunization with PLA2 are ST2 inde-
pendent, MyD88-deficientmice developed protective responses
equivalent to those seen in WT mice (Figure S4C).
Finally, because previous studies have suggested that lower
doses of antigen can bias antibody production toward IgE in
mice (Dudler et al., 1995), we were also interested in determining
whether immunizations with lower doses of bvPLA2 would lead
to either hypersensitivity or enhanced protection. However, we
observed that protection was reduced when using lower doses
of bvPLA2 for immunization (Figure S4D), and there was no
evidence of systemic anaphylaxis in these mice. Therefore, it
appears that using a lower antigen dose for immunizations
does not lead to hypersensitivity under these conditions.
DISCUSSION
We show here that bvPLA2 is a potent inducer of the type 2
immune response, including Th2 responses, ILC2 responses,
and antigen-specific IgE and IgG1 production in mice. We
confirm that the ability of bvPLA2 to induce the Th2 response
is dependent on its enzymatic activity (Dudler et al., 1995) and
show that bvPLA2 induces the Th2 response through the cleav-
age of membrane phospholipids and production of lysophos-
pholipids, such as LPC. These data suggest that the immune
system senses envenomation through detection of a molecular
activity of a venom component and support the hypothesis
that the detection of enzymatic activities of allergens by the
innate immune system can lead to the initiation of Th2 and IgE
responses (Shakib et al., 2008; Wills-Karp et al., 2010). We find
that a PLA2 from snake venom can also induce a Th2 response.
Because PLA2 is a common component of venoms from diverse
species, sensing of PLA2 activitymight allow the immune system
to detect venoms frommultiple species by using a single sensing
mechanism. This feature of PLA2 detection is reminiscent of
pattern recognition of conserved PAMPs (Janeway, 1989),
except that conserved enzymatic activities are detected instead
of conserved molecular patterns. Based on these data, we
propose that the phospholipase activity of PLA2s represents a
Th2-inducing activity that is conserved among a class of aller-
gens, similar to protease activity found in another major class
of allergens.
The molecular mechanisms involved in innate sensing of aller-
gens and instruction of Th2 responses remain largely unknown.
We examined the role of innate immune receptors and adaptors
in the activation of bvPLA2-induced Th2 responses. We found a
critical role for the TLR and IL-1R family adaptor protein MyD88
in response to bvPLA2 immunization. Surprisingly, although we
previously found that total IgE production in response to papain
is MyD88-independent (Sokol et al., 2008), we found that
papain-induced antigen-specific Th2 responses are MyD88-
dependent.
Recent studies have highlighted the critical role of IL-33/ST2 in
type 2 inflammation and allergic disease states. IL-33 plays a
significant role in innate type 2 responses by inducing the expan-982 Immunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc.sion of type 2 innate lymphoid cells, which produce IL-5 and
IL-13 and contribute to respiratory and gastrointestinal inflam-
mation and antihelminth responses (Oliphant et al., 2011).
Furthermore, a role for MyD88 and ST2 in driving the Th2
response to Trichinella spiralis has recently been demonstrated
(Scalfone et al., 2013). We find here that ST2 is required for the
induction of bvPLA2- and LPC-induced Th2 responses. Further-
more, we show that MyD88 expression in T cells is required for
optimal Th2 responses to bvPLA2. This suggests that the Th2-
inducing effects of IL-33 in response to bvPLA2 are largely
dependent on the effect of IL-33 on T cells themselves.
Our findings suggest a model in which bvPLA2 hydrolyzes
membrane phospholipids to produce lysophospholipids (such
as LPC), which then induce the release of IL-33 through disrup-
tion of cellular membranes and induction of cell death. IL-33 then
supports Th2 differentiation by signaling through ST2 on T cells.
IL-33 can be released from damaged, mechanically disturbed,
and necrotic cells and, thus, can act as an ‘‘alarmin’’ (Zhao
and Hu, 2010; Kakkar et al., 2012). Immunization with bvPLA2
or LPC likely leads to cell death in affected tissues. Our data
thus support the hypothesis that bvPLA2-induced cell death
might be responsible for its ability to induce Th2 responses.
Notably, we found that Phospholipase D, which also cleaves
membrane phospholipids, is also a potent inducer of the Th2
response. This raises the possibility that cell death resulting
from disruption of cellular membranes might be a shared feature
of some of the Th2-inducing stimuli. Importantly, however, not all
triggers of cell death are equally potent inducers of the Th2
response. For example, although melittin is an effective inducer
of cell death, we found that it was less efficient than PLA2 at
inducing the type 2 immune response. This suggests that only
certain forms of cell death result in induction of a Th2 response.
Interestingly, LPC is also found in the saliva of some hema-
tophagous insects, such as the ‘‘kissing bug’’ Rhodnius prolixus,
and plays an important role in themodulation of the host immune
response (Mesquita et al., 2008). It would be interesting to inves-
tigate whether LPC present in the saliva of blood-sucking insects
contributes to type 2 immune responses elicited by their bites.
While we observed that bvPLA2-induced ILC2 and primary
Th2 responses were dependent on ST2, the IgE response
appeared to be largely unaffected by ST2-deficiency. A likely
explanation for this difference is that ST2 is required for primary
but not secondary T cell responses. Because the IgE response
is undetectable after primary immunization (data not shown), it
was not possible to examine whether it was ST2 dependent.
When we examined the secondary Th2 response induced by
bvPLA2, we found that it was also largely independent of ST2.
This suggests that the Th2 response in ST2-deficient mice might
recover to normal levels upon repeated immunization. It is thus
possible that the primary IgE response is defective in ST2-defi-
cient mice but falls below the limit of detection. Alternatively,
the IgE response might simply not require ST2.
Because allergens are generally thought of as innocuous,
immune responses to allergens (that is, allergic responses) are
considered to be accidental and pathological. However, many
allergens, including venoms, are clearly noxious. This observa-
tion has lead to the hypothesis that one purpose of the type 2
immune response to allergens is to protect the host against
toxins and other noxious environmental substances (Palm
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Venom Phospholipase A2-Induced Type 2 Responseset al., 2012; Profet, 1991). The type 2 immune response might
play beneficial roles in response to envenomation by leading to
detoxification of venom components (Higginbotham and Kar-
nella, 1971), enhancing clearance of toxins (Palm et al., 2012),
activating tissue repair mechanisms (Allen and Wynn, 2011),
and inducing avoidance to prevent future exposure (Profet,
1991). We found that immunization of mice with bvPLA2 leads
to protection from subsequent challenge with a near-lethal
dose of bvPLA2 and that this protection is partially dependent
on FcεR1a expression and B cells. Taken together, our data
suggest that the IgE response can provide protection from the
noxious effects of envenomation, presumably through bvPLA2-
specific IgE-mediated mast cell degranulation.
What determines whether the IgE response leads to protective
immunity or pathological anaphylaxis in mice remains to be
elucidated. Although PLA2 immunization induces protection in
C57Bl/6 background mice, we noted that repeated immuniza-
tions with bvPLA2 occasionally resulted in development of
hypersensitivity to bvPLA2 in Balb/c mice. Thus, genetic factors
might play an important role in determining whether the
IgE response to envenomation leads to protective or anaphy-
lactic responses. How our findings translate to the human
immune response to venom allergens remains to be determined.
For example, it is thought that repeated immunizations with high
doses of antigen are effective at preventing anaphylaxis in
humans in the setting of venom immunotherapy because they
lead to the induction of IgG responses, which compete with
IgE for allergen binding (Ozdemir et al., 2011). Furthermore,
whereas we could not find a major role for protective IgG
responses in mice, bvPLA2-neutralizing IgG antibodies have
been observed in humans (Mohammed and El-Karemi, 1961).
Thus,murine and human immune responses to bee venommight
differ substantially, perhaps reflecting the distinct role of
venomous snakes in the ecology of rodents and primates.
Taken together, our data suggest that the immune system has
evolved a mechanism to detect a conserved, noxious compo-
nent of venoms and that sensing of the noxious effects of
venoms leads to the induction of a type 2 immune response
that can protect against future venom exposure. IL-33 release
after cell death might represent one mechanism by which
noxious xenobiotics, such as venoms, are sensed by the im-
mune system and induce a type 2 immune response. Thus, these
studies reveal a potential mechanistic link between noxious
activities and the induction of a type 2 immune response and
support the emerging connection between type 2 immunity
and sensing of tissue damage (Allen and Wynn, 2011; Palm
et al., 2012).EXPERIMENTAL PROCEDURES
Mice
Mice were bred at the Yale Animal Resources Center at Yale University in
specific pathogen-free conditions, and all experiments were done in accor-
dance with approved guidelines, regulations, and protocols as determined
by the Institutional Animal Care and Use Committee at Yale. BALB/c and
C57BL/6 mice were purchased from NCI or Jackson Laboratories; Fcer1a/,
Ighm/ (muMT), Il1r1/, and Il18r1/ mice were from Jackson. Il1rl1/
mice were kindly provided by Andrew McKenzie (University of Cambridge)
via Paul Bryce (Northwestern University); Myd88/ Balb/c mice were from
Mark Shlomchik (Yale University); Ripk3/ mice were from Vishva DixitI(Genentech); and Gpr132/ mice were from Janusz Kabarowski (University
of Alabama). 4get mice (Mohrs et al., 2001), Myd88/;Trif/, Myd88/
C57BL/6, Tlr2/;Tlr4/, and Tlr9/ mice were bred in our colony.
MyD88fl/fl;Cd4-Cre mice were constructed by D.D.S. (unpublished data).
Reagents and Antibodies
Bee venom phospholipase A2 (bvPLA2), bee venom, lysophosphatidylcholine
(LPC), melittin, arachidonic acid (AA), Crotalus atrox venom, Agkistrodon
contortrix venom, Crotalus adamanteus venom, and o-phenylenediamine
dihydrochloride (OPD) were purchased from Sigma. Low endotoxin (endog-
rade) OVA was from Biosource. Papain was purchased from Calbiochem.
The following reagents are from the indicated sources: DX5 beads (Miltenyi
Biotec), Ack lysing buffer (Lonza), FCS (Benchmark), recombinant IL-4, IL-5,
IL-13, and IL-33 (R&D Systems), recombinant IL-3 (Peprotech), RNA-Bee
(Tel-TesT), SMART MMLV RT reagents (Clontech), SYBR Green QPCR mix
(Quanta), endograde OVA (Biovendor, LLC), Crotalus PLA2 (Worthington
Biochemical), Lipofectamine 2000 and pcDNA3.1/V5-His C (Invitrogen), and
mIL-33 ELISA antibody pairs (R&D Systems). Dx5-APC, CD4-APC, Streptavi-
din-HRP, ELISA antibody pairs (mIL-4, mIL-13), biotinylated anti-mouse IL-5,
anti-CD16/32 from ebioscience and IgE-bio, Streptavidin-PerCP, purified
mouse IgE, purified rat anti-mouse IL-5 from BD PharMingen. IgG1 and to-
tal-IgE ELISA antibody pairs were from Southern Biotech.
T Cell Assays
For in vitro restimulation of T cells, mice were immunized subcutaneously in
both hind footpads with 50 ml PBS/site containing 50 mg endograde OVA alone
or in combination with 50 mg bvPLA2 or 500 nmol LPC. Inguinal and popliteal
lymph nodes were isolated 6 days after immunization. Total lymph node CD4+
T cells were isolated by incubating cells with anti-CD4 magnetic beads
followed by positive selection by AutoMACS (Miltenyi biotec). Purified CD4+
T cells (1.5 3 105) were cocultured with irradiated (850 rads) splenocytes
(3 3 105) and titrating doses of OVA (Sigma; 900 mg/mL-100 mg/mL) in round
bottom 96-well plates for 5–6 days before analysis of secreted cytokines.
For analysis of GFP+ T cells from 4get mice, 50 mgOVA, 50 mg bvPLA2, 50 mg
melittin, 50 mg bee venom, 125 mg Crotalus PLA2, 500 nmol LPC, or 500 nmol
AA were injected in both hind footpads, while 25 mgC. atrox or A. conto venom
was injected in only one footpad. LPC and AA were injected in the presence of
50 mg OVA. Heat-inactivation of bvPLA2 was achieved by incubating at 100C
for 3 hr. Popliteal lymph nodes were isolated and stained 4–5 days after immu-
nization. Lymph node single cell suspensions were incubated with anti-CD16/
32 Fc block before staining with CD4-APC to detect GFP+ T cells.
Antibody Production
For analysis of antibody production, mice were immunized subcutaneously as
above with 50ug/site of bvPLA2, melittin, bee venom, HSA, or papain on day
0 and day 21. For analysis of OVA-specific antibody production, mice were
immunized as above in the presence of 50ug endograde OVA. Sera were
analyzed as indicated by ELISA.
Protection Assays
For protection assays, mice were immunized intraperitoneally (i.p.) with 50 mg
bvPLA2 weekly for 6 weeks and challenged on days 37–40. Mice were chal-
lenged i.p. with bvPLA2 with a dose adjusted to mouse weight (150 mg
PLA2/250 ml PBS/25 g mouse). Rectal temperatures were followed for 5–6 hr
and then daily for 72 hr after immunization. At rectal temperatures below
26.5C, mice were euthanized and considered to have had a lethal response.
IL-33 Release Assays
For analysis of intraperitoneal IL-33 release, C57Bl/6 mice were immunized
with bvPLA2 (100 mg at 1 mg/mL) or LPC (100 mg at 1 mg/ml) i.p. At the spec-
ified time points after immunization, mice were euthanized and peritoneal
cytokines were isolated by washing the peritoneum with PBS. Peritoneal fluid
IL-33 was analyzed by ELISA.
To analyze IL-33 release in vitro, we utilized a stable cell line overexpressing
full-length mouse IL-33 (Mus musculus IL33, CCDS ID CCDS29740). This cell
line was generated by cloningmil-33 into pcDNA3.1/V5-His Cwith subsequent
transfection of the construct into 293 cells (Lipofectamine transfection) and
clonal selection with G418. Cells were stimulated with OVA, bvPLA2, or LPCmmunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc. 983
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collected from cell cultures and IL-33 release was analyzed by ELISA.
Dendritic Cell Activation and Basophil Migration
For analysis of lymph node DCs and basophils, mice were immunized subcu-
taneously as above with the addition of papain (100 mg/ms) and LPS
(20 mg/ms). Popliteal lymph node single cell suspensions were stained after
18 hr with CD11c-APC, CD80-PE, and CD86-FITC to detect DCs and after
3 days with DX5-APC and IgE-FITC to detect basophils.
Enzyme-Linked Immunosorbent Assays
Supernatants were collected from T cell cocultures 4–5 days after plating and
were added to Nunc Maxisorp 96-well plates, which had been coated with
purified anti-mouse IL-4 antibody (2 mg/mL), IL-5 (2 mg/mL), or IL-13
(4 mg/mL) and subsequently blocked with 1% BSA. Cytokines were detected
with biotinylated anti-mouse IL-4 (.5 mg/mL), IL-5 (1 mg/mL), and IL-13
(.5 mg/mL). For detection of IL-33, cell supernatants or intraperitoneal fluid
samples were isolated at the specified time points and plated on Maxisorp
plates that had been coatedwith purified anti-mouse IL-33 (.8 mg/mL); cytokine
was detected with biotinylated anti-mouse IL-33 (.5 mg/mL). Antibody binding
was detected with streptavidin-HRP and developed with OPD.
For serum OVA-specific IgG1 antibody detection, plates were coated with
OVA, blocked, and eight 3-fold serial dilutions of sera were added (1:50 start-
ing dilution). Detection was achieved with biotinylated anti-IgG1 (Southern
Biotech). Antibody binding was detected as above. OVA-specific IgE was
detected with a mouse anti-OVA IgE kit (Chondrex) as directed by the manu-
facturer. Total IgE was detected similarly to above coating with anti-mouse IgE
(Southern Biotech) and detecting with biotinylated anti-IgE (Southern Biotech).
Bone-Marrow-Derived Basophil Stimulations
Mixed mast cell and basophil cultures were derived by incubating total bone
marrow cells, which had undergone RBC lysis, in the presence of RPMI
supplemented by 30 ng/mL mIL-3 and 10% FCS, as described (Sokol et al.,
2008). Briefly, cells were plated at 53 106 cells/mL and subsequently replated
on day 3 and day 7 at 13 106 cells/mL. DX5+ basophils were sorted from these
cultures on day 10–11 by DX5 positive selection by AutoMACS. DX5+ baso-
phils were resuspended at 2 million cells/mL and stimulated with titrating
doses of HSA (250 mg/ml), OVA (250 mg/ml), total bee venom (12.5 mg/ml),
melittin (12.5 mg/ml), bvPLA2 (250 mg/mL), papain (100 mg/mL), C. atrox venom
(312.5 mg/ml), A. conto venom (156.25 mg/ml), lysophosphatidylcholine
(200 mM), and arachidonic acid (200 mM). Doses that induced the greatest
amount of IL-4 production (as measured by ELISA) are shown in parentheses
above and are presented in the figures. IL-4 production was analyzed by ELISA
6 hr after stimulation, as described above, or qPCR analysis of RNA induction
at 1 and 3 hr after stimulation. Briefly, total RNA was extracted with RNA-Bee
and reverse transcribed with an oligo (dT) primer. cDNA was analyzed by
qPCR amplification with SYBR Green QPCR Master Mix on an MX300P
QPCR System (Stratagene) with analysis by comparative quantification with
MXPro software. Unstimulated samples were used as calibrators and samples
were normalized to b-actin expression. Primers used for RT-PCR analysis
were as follows: il-4, 50-AGATGGATGTGCCAAACGTCC-30, 50-GAAAAGCCC
GAAAGAGTCTCTGC-30; b-actin, 50-GAAGTCCCTCACCCTCCCAA-30, 50-GG
CATGGACGCGACCA-30.
bvPLA2-Induced Inflammation and Activation of ILC2s
Mice were injected i.p. with PBS, 50 mg, or 100 mg bvPLA2 for 3 consecutive
days. Cells were harvested on day 4 by injecting 2ml of PBS into the peritoneal
cavity. Total and differential cell counts were determined by flow cytometry
(BD Accuri C6) and cytospin preparations stained with eosin and hematoxylin
(Diff-quick protocol). Peritoneal cells were resuspended in RPMI containing
10% FBS and incubated overnight with 50 ng/mL PMA and 500 ng/mL iono-
mycin or 10 ng/mL of murine recombinant IL-7 and IL-33 (both cytokines
from Biolegend). Single-cell suspensions were stained with fluorochrome-
conjugated antibodies against the following surface molecules: lineage
markers (CD3e, CD19, CD11b, CD11c, Ly-6G, NK1.1, FceRI), CD90.2 (Thy-
1.2), CD45, ICOS, and c-kit in staining buffer. Cells were then fixed and
permeabilized for intracellular staining of IL-5 and IL-13 according to the man-
ufacturer’s instructions (BD Cytofix/Cytoperm Protocol). All antibodies used984 Immunity 39, 976–985, November 14, 2013 ª2013 Elsevier Inc.were from eBioscience or BD Biosciences. Cell acquisition was performed
on LSRII instruments (BD), and data were analyzed with FlowJo software
(TreeStar).
Statistical Analysis
Statistical analyses were performed with ANOVA or t tests, as appropriate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
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